Efficacy of magnesium-calcium ionic oral rinse for primary burning mouth syndrome: a randomized, double-blind, placebo-controlled trial.

Neus Carrió, Basel El Garawani, Ayman Alahmad, Fares Atari, Eduard Ferrés-Amat, Joseph Bassil, Islam A Amer, Mai Badrah, Alshaimaa A Shabaan, Islam Kassem

Journal: BMC oral health 2026;26(1):

PMID: 42472793

Abstract

INTRODUCTION

Primary burning mouth syndrome (BMS) is a chronic idiopathic orofacial pain condition characterized by persistent intraoral burning sensation in the absence of clinically evident mucosal lesions. Its pathophysiology is considered multifactorial, with neuropathic mechanisms playing a central role. Current treatments are constrained by systemic adverse effects. Modulation of the oral mucosal ionic microenvironment has been proposed as a potential local therapeutic strategy. This study aimed to evaluate the efficacy and safety of magnesium-calcium oral rinse(test oral rinse)in patients with primary BMS.

MATERIALS AND METHODS

In this randomized, double-blind, placebo-controlled trial, 116 adults with primary burning mouth syndrome (BMS) were assigned in a 1:1 ratio to receive magnesium-calcium oral rinse or placebo for 8 weeks. Participants rinsed 10 mL for 60 seconds three times daily. The primary outcome was change in burning pain intensity assessed using a Numeric Rating Scale (NRS). Secondary outcomes included the responder rate (≥2-point reduction in NRS), Oral Health Impact Profile-14 (OHIP-14), Xerostomia Inventory, Patient Global Impression of Change (PGIC), and safety assessments.

RESULTS

At week 8, the active group showed significantly greater reduction in pain compared with placebo (mean difference, -1.7; 95% CI, -2.5 to -0.9; P<0.001). Responder rates were 62% versus 32% (P=0.001). Significant improvements were also observed in OHIP-14 and xerostomia scores. Adverse events were mild and comparable between groups.

CONCLUSION

Magnesium-calcium oral rinse significantly reduced burning pain and improved oral health-related quality of life in patients with primary burning mouth syndrome, with a favorable safety profile. These findings support the potential role of mineral-ionic topical therapy in this condition.

TRIAL REGISTRATION

ClinicalTrials.gov NCT07564843, registered on 27 Abril 2026. Retrospectively registered.

© 2026. The Author(s).

Address: Periodontology Department, Universitat Internacional de Catalunya (UIC), C/Josep Trueta s/n, Barcelona, 08195, Spain.; Maxillofacial Surgery Department, Alexandria University Hospital, Alexandria University, Alexandria, Egypt.; King Hussein Medical Center, Amman, Jordan.; Al-Balqa' Applied University, Al Salt, Jordan.; Oral Surgery Department, Universidad Católoca San Antonio Murcia, Murcia, Spain.; Faculty of Dental Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.; General Surgery Department, Faculty of Medicine, Sohag University, Sohag, Egypt.; Internal Medicine Diabetes and Metabolism Department, Alexandria University, Alexandria, Egypt.; Oral & Maxillofacial Surgery Department, Fayoum University, Fayoum, Egypt.; Maxillofacial Surgery Department, Alexandria University Hospital, Alexandria University, Alexandria, Egypt. [email protected].

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.